Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2000

View Archived Issues

NIH offers type I TNF receptor regulator for licensing

Wnt protein signaling found to control adipogenesis

Researchers discover protein required for protein translocation in bacteria

Licensing opportunity from NIH: gene amplification in cancer

NIH licensing opportunity: methods to inhibit cell motility

Atrix to use drug delivery technology to develop products for Pfizer

NIH licensing opportunity: system for functional identification of p53 mutations

NIH licensing opportunity: novel methods for MRA use in vessel delineation

CPMP recommends marketing approval for Serono's new treatment of female infertility

Viragen to file IND for Omniferon, enroll additional patients in HCV trial

Tularik initiates phase I study of anti-cytomegalovirus compound

Triangle Pharmaceuticals to proceed with Coactinon development

Novavax begins clinical trials of testosterone HRT

EpiCept to begin clinical development of cancer pain therapy

Zonagen receives SBIR grant to study SPRMs for endometriosis

GPC Biotech and Bayer establish antibacterial collaboration agreement

Swiss agency issues preapproval letter for Forcaltonin

Novartis on schedule for 2001 launch of Zelmac

Novel cell adhesion antagonists described

New compounds interacting with 5-HT4 receptor useful for gastrointestinal disorders

New series of tricyclic vasopressin agonists under study at AHP

New selective 5-HT3 antagonists useful as antiemetics

Novel AMPA antagonists under study at Kyorin

Novel antifungal agents under development at SS Pharmaceutical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...